ライフサイエンスコーパス: active vitamin

1 All-trans-retinoic acid (ATRA) is an active vitamin A derivative known to modulate a number o

2 Retinoic acid (RA), an active vitamin A derivative, is essential for mammalian

3 kers were found for riboflavin, vitamin B-6, active vitamin B-12 (holotranscobalamin), and betaine.

4 ammalian enzymes that utilise a biologically active vitamin B-12 derivative.

5 scobalamin 2 (TCN2), which is referred to as active vitamin B-12.

6 As confirmed by UHPLC-MS, the active vitamin B12 could be separated from pseudovitamin

7 and validated for the determination of human active vitamin B12 in cell extracts of Propionibacterium

8 form, adding complexity to our assessment of active vitamin B12 in the environment.

9 A nutritionally relevant amount of active vitamin B12 was produced by P. freudenreichii in

10 ts superiority to the MBA in determining the active vitamin B12.

11 sma folate, B12, and pyridoxal 5'-phosphate (active vitamin B6) levels, along with other potential de

12 ents with PSC and the effects of exposure to active vitamin D (1,25[OH]2D3) on expression of CD28.

13 ated hormone-controlled system that involves active vitamin D [1,25(OH)(2)D], which can elicit calciu

14 that encodes the primary catabolic enzyme of active vitamin D [25(OH)D-24-hydroxylase encoded by CYP2

15 ism by which local conversion of inactive to active vitamin D alters immune function in the lung.

16 ed more commonly in patients treated with an active vitamin D analog (204/390 patients) than control

17 Thus, active vitamin D analogs may further reduce proteinuria

18 We aimed to address whether active vitamin D analogs reduce residual proteinuria.

19 Active vitamin D analogs reduced proteinuria (weighted m

20 Active vitamin D and calcium were progressively reduced,

21 Because serum levels of active vitamin D are greatly increased upon genetic abla

22 Treatment with high-dose oral calcium and active vitamin D does not provide adequate or consistent

23 ptimisation period, during which calcium and active vitamin D doses were adjusted to achieve consiste

24 f the prohormone 25-hydroxyvitamin D and the active vitamin D hormone 1, 25-dihydroxyvitamin D.

25 berculosis H37Ra and then activated with the active vitamin D hormone 1,25-dihydroxyvitamin D(3) (1,2

26 n correlated with both circulating levels of active vitamin D hormone and in vitro measures of gene e

27 droxylase, which functions to metabolize the active vitamin D in cells.

28 m in chronic kidney failure with calcium and active vitamin D is potentially limited by hypercalcemia

29 d with increased MS susceptibility and lower active vitamin D levels.

30 triol (1alpha,25-dihydroxyvitamin D3) is the active vitamin D metabolite and mediates immunological f

31 Notably, administration of the active vitamin D metabolite calcitriol reversed all thes

32 The active vitamin D metabolite, 1,25-dihydroxyvitamin D, ac

33 of 1,25-dihydroxyvitamin D [1,25(OH)2D], the active vitamin D metabolite, from 25-hydroxyvitamin D [2

34 tes mellitus, we investigated the effects of active vitamin D on macrophage cholesterol deposition.

35 5 hydroxylase that converts vitamin D3 to an active vitamin D receptor ligand; P=1.4x10(-5)).

36 se activities to an unusual but functionally active vitamin D response element and to several potenti

37 which include 242 patients who were given an active vitamin D sterol.

38 al insufficiency (CCr, 25 to 60 ml/min), the active vitamin D sterols calcitriol or alfacalcidol [1 a

39 therapy with calcium, phosphate binders, and active vitamin D sterols, were treated in this 18-wk, do

40 reby increasing the safety of treatment with active vitamin D sterols.

41 ular epithelial cells are the major sites of active vitamin D synthesis, little is known about the ro

42 Active vitamin D that is generated by lung epithelium le

43 tion increased over time, whereas the use of active vitamin D was unchanged.

44 line in their daily dose of oral calcium and active vitamin D while maintaining a serum calcium conce

45 induction of Sult2A1 mRNAs by the hormonally active vitamin D(3) and the catatoxic synthetic steroid

46 Hormonally active vitamin D(3)-1,25-dihydroxyvitamin D(3) (1,25D3)-

47 Indeed, we found that small doses of active vitamin D, 1alpha,25-dihydroxyvitamin D3 (1,25D3)

48 DL cholesterol, and use of aspirin, statins, active vitamin D, and antihypertensive medications, in f

49 lpha-hydroxylase, augments the production of active vitamin D, and synergizes with vitamin D to incre

50 Active vitamin D, generated locally in tissues, is impor

51 clude that primary epithelial cells generate active vitamin D, which then influences the expression o

52 te that human endothelia are able to produce active vitamin D.

53 lphabeta(ep-/-)) or a topical application of active vitamin D3 (VD3) and/or all-trans retinoic acid (

54 c renal failure, where concentrations of the active vitamin D3 metabolite, 1alpha,25-dihydroxyvitamin

55 045), and suggested an increased risk in the active vitamin group (P =.09).

56 a functional vitamin K cycle to produce the active vitamin K cofactor for the gamma-carboxylase whic

57 e cycle reduces vitamin K 2,3-epoxide to the active vitamin K hydroquinone cofactor.

58 arin-treated zebrafish, which have decreased active vitamin K, display similar vascular degeneration

59 K-dependent carboxylase modifies and renders active vitamin K-dependent proteins involved in hemostas

60 is a key regulatory protein in synthesis of active vitamin K-dependent proteins.

61 Patients receiving active vitamin treatment had similar risk for the compos